Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This study found that dexamethasone treatment inhibited the inflammatory response and the induction of ornithine decarboxylase activity in mouse skin after TPA application, although the effect on ODC was weaker during the hyperplastic stage.

This study identified overlapping genetic susceptibility loci in both alopecia areata and inflammatory bowel disease, specifically with Crohn's disease and ulcerative colitis.

In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.

In this study, Cyanidin 3-O-arabinoside was found to protect against DHT-induced dermal papilla cell senescence and mitochondrial dysfunction in androgenetic alopecia, restoring hair growth in mouse models.

Apremilast may help treat hair loss in alopecia areata.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

Hair shaft malformation contributes to Central Centrifugal Cicatricial Alopecia.

The document concludes that doctors should recognize congenital triangular alopecia to avoid unnecessary treatments, as it does not respond to steroids like alopecia areata does.

In this case report, a 46-year-old woman initially diagnosed with 21-hydroxylase deficiency congenital adrenal hyperplasia was later identified as having 3β-HSD2 deficiency after further investigation, highlighting the need for awareness of rarer CAH forms to prevent delayed diagnosis and insufficient treatment.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

This review discusses methods to better identify unsafe donor areas in patients with diffuse unpatterned alopecia, emphasizing non-surgical management when specific diagnostic criteria are met, but reports no new clinical results.

This review outlines how peptidyl arginine deiminases (PADIs) and protein citrullination are involved in hair follicle regeneration and inflammatory alopecia, but presents no new clinical findings.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

Genetic changes in specific proteins contribute to hair loss in some women of African descent.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

In this study, a 15-year-old male with alopecia areata universalis showed significant hair regrowth after an 8-month combination therapy, suggesting that comprehensive treatment, including antiviral, corticosteroid, and LED therapy, may be effective albeit long-term for managing this condition.

This article reports that mutations in the PADI3 gene, affecting its activity or localization, cause uncombable hair syndrome and are linked to central centrifugal cicatricial alopecia, particularly among women of African ancestry.

This case report found that a patient with ritlecitinib-resistant alopecia areata experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential effectiveness and suggesting benefits of personalized treatment strategies targeting the JAK1-mediated pathway.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that PUVA treatment resulted in complete hair regrowth in over half of patients with alopecia areata totalis or universalis, despite a higher treatment failure rate in those with a family history of the condition.

This case report describes severe agranulocytosis and alopecia in a Japanese woman after starting azathioprine, highlighting the potential role of NUDT15 genetic screening in preventing adverse reactions to the drug.

This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.

In this study, researchers developed a novel delivery system using hyaluronic acid gels to encapsulate Huperzine A for Alzheimer's treatment, achieving extended release over 20 days and significantly improving pathology and behavior in mice, including enhanced memory and reduced neuroinflammation.

In a laboratory setting, this study reported that the n-butanol fraction of Urtica laetevirens Maxim. water extracts significantly inhibited 5α-reductase activity.